{"protocolSection": {"identificationModule": {"nctId": "NCT03568500", "orgStudyIdInfo": {"id": "031-201-00186"}, "organization": {"fullName": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic", "officialTitle": "A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adult Subjects With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic (Aripiprazole, Olanzapine, Quetiapine, or Risperidone)"}, "statusModule": {"statusVerifiedDate": "2020-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-05-21", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-05-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-09-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-05-25", "studyFirstSubmitQcDate": "2018-06-13", "studyFirstPostDateStruct": {"date": "2018-06-26", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-04-30", "resultsFirstSubmitQcDate": "2020-07-02", "resultsFirstPostDateStruct": {"date": "2020-07-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-07-02", "lastUpdatePostDateStruct": {"date": "2020-07-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use. The DMS is being developed as a healthcare management tool to precisely measure medication adherence and to potentially enhance adherence.", "detailedDescription": "The advancements in the treatment of mental health patients with DMS will enable healthcare professionals to assess suboptimal adherence and make more informed treatment decisions. In addition to these improvements, it will also provide a platform for engagement between participants, healthcare professionals, and caregivers/support persons.\n\nParticipants who entered the trial were treated with one of the oral atypical antipsychotics defined in the trial (aripiprazole, olanzapine, quetiapine, or risperidone \\[though no participant took risperidone in this trial\\]). The treatment medication decision was determined by the healthcare professionals."}, "conditionsModule": {"conditions": ["Schizophrenia", "Schizoaffective Disorder", "First Episode Psychosis"], "keywords": ["Digital Medicine System"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "HEALTH_SERVICES_RESEARCH", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 44, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aripiprazole", "type": "EXPERIMENTAL", "description": "Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.", "interventionNames": ["Device: Digital Medicine System", "Drug: Aripiprazole"]}, {"label": "Olanzapine", "type": "EXPERIMENTAL", "description": "Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.", "interventionNames": ["Device: Digital Medicine System", "Drug: Olanzapine"]}, {"label": "Quetiapine", "type": "EXPERIMENTAL", "description": "Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.", "interventionNames": ["Device: Digital Medicine System", "Drug: Quetiapine"]}, {"label": "Risperidone", "type": "EXPERIMENTAL", "description": "Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.", "interventionNames": ["Device: Digital Medicine System", "Drug: Risperidone"]}], "interventions": [{"type": "DEVICE", "name": "Digital Medicine System", "description": "DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformit\u00e9 Europ\u00e9enne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \\[Disposable Wearable Sensor Version 5\\]); proprietary medical software (a local and remote computing application).", "armGroupLabels": ["Aripiprazole", "Olanzapine", "Quetiapine", "Risperidone"]}, {"type": "DRUG", "name": "Aripiprazole", "description": "Dosage determined by the healthcare professionals.", "armGroupLabels": ["Aripiprazole"]}, {"type": "DRUG", "name": "Olanzapine", "description": "Dosage determined by the healthcare professionals.", "armGroupLabels": ["Olanzapine"]}, {"type": "DRUG", "name": "Quetiapine", "description": "Dosage determined by the healthcare professionals.", "armGroupLabels": ["Quetiapine"]}, {"type": "DRUG", "name": "Risperidone", "description": "Dosage determined by the healthcare professionals.", "armGroupLabels": ["Risperidone"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage Of Days With Good Patch Coverage", "description": "The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (miniature ingestible event marker in tablet \\[MIT\\]). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Good patch coverage for a specific day was defined as having either at least 80% patch data available (80% of the day the patch was worn and data was collected as noted via the accelerometer channel) or the MIT was detected within the 24-hour period, for each day while the participant was in the trial. The percentage of days was calculated as the number of days with good patch coverage divided by the total number of trial days for each participant. Descriptive statistics were performed for this outcome measure.", "timeFrame": "Up to 8 weeks"}], "secondaryOutcomes": [{"measure": "Participant Adherence", "description": "The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (MIT). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Participant adherence was measured as the detected MITs over the expected MITs ingested during the trial days with good patch coverage. The more the participant successfully engaged in a number of processes across the 8-week trial, the greater the measured adherence. Descriptive statistics were performed for this outcome measure.", "timeFrame": "Up to 8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participant was prescribed aripiprazole, olanzapine, quetiapine, or risperidone.\n* Participant possessed a smartphone, or a smartphone provided by the Sponsor, and was willing to download and interact with the DMS app.\n* Skin on the anterior chest just above the lower edge of the rib cage was free of any dermatological problems (for example, open wounds, warts, rashes, atopic dermatitis).\n\nExclusion Criteria:\n\n* Participant with a known allergy to adhesive tape or any pertinent components of the patch or CoE product.\n* Prisoners could not be enrolled into this trial.\n* Participant who was hospitalized due to mental or physical illness (inpatient) at the time of screening/baseline.\n* Any participant who, through religious or lifestyle choices, would not take gelatin capsules.\n* Female of childbearing potential who was breast-feeding and/or who had a positive pregnancy test result prior to receiving trial enrollment, or who planned to become pregnancy during the trial.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Clinical Trial Site", "city": "Chertsey", "country": "United Kingdom", "geoPoint": {"lat": 51.38812, "lon": -0.50782}}, {"facility": "Clinical Trial Site", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Clinical Trial Site", "city": "Newcastle Upon Tyne", "country": "United Kingdom", "geoPoint": {"lat": 54.97328, "lon": -1.61396}}, {"facility": "Clinical Trial Site", "city": "Oxford", "country": "United Kingdom", "geoPoint": {"lat": 51.75222, "lon": -1.25596}}, {"facility": "Clinical Trial Site", "city": "Southampton", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "referencesModule": {"references": [{"pmid": "31253613", "type": "DERIVED", "citation": "Fowler JC, Cope N, Knights J, Phiri P, Makin A, Peters-Strickland T, Rathod S. Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis. BMJ Open. 2019 Jun 27;9(6):e025952. doi: 10.1136/bmjopen-2018-025952."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.", "accessCriteria": "Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.", "url": "https://clinical-trials.otsuka.com"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants in this trial received at least 1 CoEncapsulated miniature ingestible event marker in a tablet and a medicinal product originator tablet of either aripiprazole, olanzapine, or quetiapine (participants were allowed to take risperidone, though no participant took risperidone in this trial) as prescribed by their healthcare professional.", "recruitmentDetails": "The trial enrolled participants with a confirmed clinical diagnosis of schizophrenia, schizoaffective disorder, or first episode psychosis.", "groups": [{"id": "FG000", "title": "Aripiprazole", "description": "Participants were treated with at least 1 CoEncapsulated (CoE) oral aripiprazole tablet, wearing the digital medicine system (DMS) patch, and using the associated smartphone app for a total of 8 weeks."}, {"id": "FG001", "title": "Olanzapine", "description": "Participants were treated with at least 1 CoE oral olanzapine tablet, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks."}, {"id": "FG002", "title": "Quetiapine", "description": "Participants were treated with at least 1 CoE oral quetiapine tablet, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "20"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "Received At Least 1 Dose of Study Drug", "comment": "Safety Population: All participants who entered the trial and used the DMS.", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Technical Problems", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Participant Noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Enrolled Population: All participants who signed an informed consent form and entered the trial (and only participants who met all of the inclusion criteria and none of the exclusion criteria).", "groups": [{"id": "BG000", "title": "Aripiprazole", "description": "Participants were treated with at least 1 CoEncapsulated (CoE) oral aripiprazole tablet, wearing the digital medicine system (DMS) patch, and using the associated smartphone app for a total of 8 weeks."}, {"id": "BG001", "title": "Olanzapine", "description": "Participants were treated with at least 1 CoE oral olanzapine tablet, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks."}, {"id": "BG002", "title": "Quetiapine", "description": "Participants were treated with at least 1 CoE oral quetiapine tablet, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "44"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.6", "spread": "9.6"}, {"groupId": "BG001", "value": "38.0", "spread": "11.4"}, {"groupId": "BG002", "value": "30.8", "spread": "8.8"}, {"groupId": "BG003", "value": "34.4", "spread": "10.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "15"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "29"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "40"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "4"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "8"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "35"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}]}, {"title": "Disease Diagnosis", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Schizophrenia", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "18"}]}, {"title": "Schizoaffective Disorder", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "10"}]}, {"title": "First Episode Psychosis", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "16"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage Of Days With Good Patch Coverage", "description": "The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (miniature ingestible event marker in tablet \\[MIT\\]). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Good patch coverage for a specific day was defined as having either at least 80% patch data available (80% of the day the patch was worn and data was collected as noted via the accelerometer channel) or the MIT was detected within the 24-hour period, for each day while the participant was in the trial. The percentage of days was calculated as the number of days with good patch coverage divided by the total number of trial days for each participant. Descriptive statistics were performed for this outcome measure.", "populationDescription": "Intent-to-treat (ITT) Population: All participants who entered the trial and used the DMS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "Up to 8 weeks", "groups": [{"id": "OG000", "title": "Schizophrenia", "description": "Participants had a confirmed clinical diagnosis of schizophrenia (defined by International Classification of Disease-10 codes F20 and F25). There was no limit on the duration of illness. Participants were treated with at least 1 CoE oral atypical antipsychotic tablet (aripiprazole, olanzapine, or quetiapine), wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. The treatment medication decision was determined by the healthcare professional."}, {"id": "OG001", "title": "Schizoaffective Disorder", "description": "Participants had a confirmed clinical diagnosis of schizoaffective disorder (defined by International Classification of Disease-10 codes F20 and F25). There was no limit on the duration of illness. Participants were treated with at least 1 CoE oral atypical antipsychotic tablet (aripiprazole, olanzapine, or quetiapine), wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. The treatment medication decision was determined by the healthcare professional."}, {"id": "OG002", "title": "First Episode Psychosis", "description": "Participants had a confirmed clinical diagnosis of first episode psychosis using case note review. The duration of illness was defined as less than 3 years since presentation to the mental health team or first antipsychotic prescription. Participants were treated with at least 1 CoE oral atypical antipsychotic tablet (aripiprazole, olanzapine, or quetiapine), wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. The treatment medication decision was determined by the healthcare professional."}, {"id": "OG003", "title": "Total", "description": "Participants were treated with at least 1 CoE oral atypical antipsychotic tablet (aripiprazole, olanzapine, or quetiapine), wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. The treatment medication decision was determined by the healthcare professional."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "43"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "64.34", "spread": "20.24"}, {"groupId": "OG001", "value": "62.99", "spread": "37.68"}, {"groupId": "OG002", "value": "62.51", "spread": "27.53"}, {"groupId": "OG003", "value": "63.37", "spread": "26.60"}]}]}]}, {"type": "SECONDARY", "title": "Participant Adherence", "description": "The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (MIT). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Participant adherence was measured as the detected MITs over the expected MITs ingested during the trial days with good patch coverage. The more the participant successfully engaged in a number of processes across the 8-week trial, the greater the measured adherence. Descriptive statistics were performed for this outcome measure.", "populationDescription": "Intent-to-treat (ITT) Population: All participants who entered the trial, used the DMS, and had data available at the specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of MITs", "timeFrame": "Up to 8 weeks", "groups": [{"id": "OG000", "title": "Schizophrenia", "description": "Participants had a confirmed clinical diagnosis of schizophrenia (defined by International Classification of Disease-10 codes F20 and F25). There was no limit on the duration of illness. Participants were treated with at least 1 CoE oral atypical antipsychotic tablet (aripiprazole, olanzapine, or quetiapine), wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. The treatment medication decision was determined by the HCP."}, {"id": "OG001", "title": "Schizoaffective Disorder", "description": "Participants had a confirmed clinical diagnosis of schizoaffective disorder (defined by International Classification of Disease-10 codes F20 and F25). There was no limit on the duration of illness. Participants were treated with at least 1 CoE oral atypical antipsychotic tablet (aripiprazole, olanzapine, or quetiapine), wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. The treatment medication decision was determined by the HCP."}, {"id": "OG002", "title": "First Episode Psychosis", "description": "Participants had a confirmed clinical diagnosis of first episode psychosis using case note review. The duration of illness was defined as less than 3 years since presentation to the mental health team or first antipsychotic prescription. Participants were treated with at least 1 CoE oral atypical antipsychotic tablet (aripiprazole, olanzapine, or quetiapine), wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. The treatment medication decision was determined by the HCP."}, {"id": "OG003", "title": "Total", "description": "Participants were treated with at least 1 CoE oral atypical antipsychotic tablet (aripiprazole, olanzapine, or quetiapine), wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. The treatment medication decision was determined by the healthcare professional."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88.94", "spread": "8.06"}, {"groupId": "OG001", "value": "72.29", "spread": "25.65"}, {"groupId": "OG002", "value": "91.04", "spread": "7.37"}, {"groupId": "OG003", "value": "86.57", "spread": "14.47"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Baseline to Week 24 (+ 7 days)", "eventGroups": [{"id": "EG000", "title": "Aripiprazole", "description": "Participants were treated with at least 1 CoEncapsulated (CoE) oral aripiprazole tablet, wearing the digital medicine system (DMS) patch, and using the associated smartphone app for a total of 8 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 4, "otherNumAtRisk": 18}, {"id": "EG001", "title": "Olanzapine", "description": "Participants were treated with at least 1 CoE oral olanzapine tablet, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 19, "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 2, "otherNumAtRisk": 19}, {"id": "EG002", "title": "Quetiapine", "description": "Participants were treated with at least 1 CoE oral quetiapine tablet, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 3, "otherNumAtRisk": 6}, {"id": "EG003", "title": "Total", "description": "Participants were treated with at least 1 CoE oral atypical antipsychotic tablet (aripiprazole, olanzapine, or quetiapine), wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. The treatment medication decision was determined by the healthcare professional.", "deathsNumAffected": 0, "deathsNumAtRisk": 43, "seriousNumAffected": 0, "seriousNumAtRisk": 43, "otherNumAffected": 9, "otherNumAtRisk": 43}], "otherEvents": [{"term": "Medical device site irritation", "organSystem": "General disorders", "sourceVocabulary": "MedDra 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 11, "numAffected": 9, "numAtRisk": 43}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations."}, "pointOfContact": {"title": "Global Clinical Development", "organization": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "email": "clinicaltransparency@otsuka-us.com", "phone": "1-609-524-6788"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol: Version 1.0", "date": "2017-12-01", "uploadDate": "2020-04-13T10:46", "filename": "Prot_000.pdf", "size": 2991906}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol: Version 2.0", "date": "2019-01-04", "uploadDate": "2020-04-13T10:49", "filename": "Prot_001.pdf", "size": 5500256}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-06-30", "uploadDate": "2020-04-13T11:29", "filename": "SAP_002.pdf", "size": 2719248}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}, {"id": "D000011618", "term": "Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}], "browseLeaves": [{"id": "M4815", "name": "Mental Disorders", "asFound": "Psychosis", "relevance": "HIGH"}, {"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M14473", "name": "Psychotic Disorders", "asFound": "Schizoaffective Disorder", "relevance": "HIGH"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077152", "term": "Olanzapine"}, {"id": "D000018967", "term": "Risperidone"}, {"id": "D000068180", "term": "Aripiprazole"}, {"id": "D000069348", "term": "Quetiapine Fumarate"}], "ancestors": [{"id": "D000012702", "term": "Serotonin Antagonists"}, {"id": "D000018490", "term": "Serotonin Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000018492", "term": "Dopamine Antagonists"}, {"id": "D000015259", "term": "Dopamine Agents"}, {"id": "D000000932", "term": "Antiemetics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000005765", "term": "Gastrointestinal Agents"}, {"id": "D000017367", "term": "Selective Serotonin Reuptake Inhibitors"}, {"id": "D000014179", "term": "Neurotransmitter Uptake Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000018491", "term": "Dopamine Agonists"}, {"id": "D000058825", "term": "Serotonin 5-HT1 Receptor Agonists"}, {"id": "D000017366", "term": "Serotonin Receptor Agonists"}, {"id": "D000058830", "term": "Serotonin 5-HT2 Receptor Antagonists"}, {"id": "D000065127", "term": "Dopamine D2 Receptor Antagonists"}], "browseLeaves": [{"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M229", "name": "Aripiprazole", "asFound": "Association", "relevance": "HIGH"}, {"id": "M20999", "name": "Risperidone", "asFound": "Stable", "relevance": "HIGH"}, {"id": "M1675", "name": "Olanzapine", "asFound": "Cavity", "relevance": "HIGH"}, {"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Sexual", "relevance": "HIGH"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20596", "name": "Dopamine Antagonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}, {"id": "M4251", "name": "Antiemetics", "relevance": "LOW"}, {"id": "M8881", "name": "Gastrointestinal Agents", "relevance": "LOW"}, {"id": "M19649", "name": "Selective Serotonin Reuptake Inhibitors", "relevance": "LOW"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M20595", "name": "Dopamine Agonists", "relevance": "LOW"}, {"id": "M29240", "name": "Serotonin 5-HT1 Receptor Agonists", "relevance": "LOW"}, {"id": "M19648", "name": "Serotonin Receptor Agonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnEm", "name": "Antiemetics"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}